Jennifer W. Carlisle, MD, Offers Perspective on Lung Cancer Advances in 2020


The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.

2020 was a remarkable year for patients with lung cancer. Ten FDA approvals gave patients and providers new and effective treatment options, and a deeper and more nuanced understanding of lung cancer as a disease led to the identification 2 new targetable mutations – paving the way for additional treatment options down the road.

In an interview with CancerNetwork®, Jennifer W. Carlisle, MD, of the Emory University Winship Cancer Institute discussed the remarkable treatment advances for patients with lung cancer that were made over the last year, the impact those treatments may have, and the hope for an even better year ahead.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Related Content